secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001193125-24-260417
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Phase 1 in vivo CRISPR therapy nex-z shows disease stabilization in ATTR amyloidosis
--------------------------------------------------------------------------------

- Single dose of nex-z achieved mean 90% serum TTR reduction at month 12 in ATTR-CM (n=36); sustained >24 months.
- 81% of ATTR-CM patients stable/improved in NT-proBNP, 94% in hs-Troponin T at month 12; hospitalization rate 0.16/yr.
- In ATTRv-PN, mean TTR reduction 91% at month 12 (n=33); neuropathy scores stable or improved through month 24.
- Favorable safety: infusion-related reactions mild/moderate, no discontinuations; Phase 3 MAGNITUDE trials ongoing.
- Data published in NEJM and presented at AHA 2024; supports hypothesis greater TTR reduction yields greater clinical benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/0001193125-24-260417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312524260417/d828128d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-260417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer